Gila Therapeutics

• NCT07728383

  Phase 4, Recruiting, 40 people, 27 Jul 2026

• Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study

  Consulting or advice, Fees or honoraria, Patents or royalties, 9 Sept 2026

• A Randomized Controlled Trial to Evaluate the Effects of Full-Fat and Low-Fat Fermented Dairy Foods on Markers of Cardiometabolic Health in Adults with Overweight or Obesity and Elevated Fasting Triglycerides

  Consulting or advice, Board or leadership role, 14 Aug 2026

• Selective remodelling of the adipose niche in obesity and weight loss

  Consulting or advice, Board or leadership role, 9 Jul 2025

• Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

  Consulting or advice, Fees or honoraria, 10 Oct 2022

Sources: europepmc.org, pubmed.ncbi.nlm.nih.gov